Home » Newsletters » BioWorld Science

BioWorld Science

June 26, 2013

View Archived Issues

Novel TSPO PET radioligand described with low sensitivity to human genotypes

Janssen Research & Development joins MMRF's pre-competitive consortium for multiple myeloma

Results presented for clinical study of macimorelin in the treatment of cancer cachexia

InSite Vision regains rights to AzaSite Xtra

Luoxis Diagnostics reports results from first study of its proprietary diagnostic platform

Shield Therapeutics completes phase III enrollment for ST-10 in iron-deficient anemia

Tanzisertib proves to be well tolerated in vivo but clinical results lead to discontinuation

Phase II data reported for etrolizumab in ulcerative colitis

Results of a phase II study of brodalumab for asthma presented

A novel potent LPL activator improves plasma lipid levels in vivo

Researchers from Korea present phase II data for lobeglitazone

ACIP recommends Flublok influenza vaccine for adults with egg allergy

Anthera Pharmaceuticals begins phase II BRIGHT-SC study in IgA nephropathy

AtheroNova begins phase I study of AHRO-001

National Eye Institute supports stem cell research for patients with corneal blindness

FDA grants fast track designation to RBX-2660

Phase II results for C-Cure in heart failure reported, phase III study advances

Verona Pharma doses first patient in VRP-700 trial

DiaMedica provides update on DM-199 program for type 2 diabetes

Bristol-Myers Squibb patents new MGAT2 inhibitors

Novel opsin protein ligands designed by BIKAM Pharmaceuticals

Avanir's Nuedexta approved by the European Commission for pseudobulbar affect

Roche synthesizes novel BTK inhibitors

FDA approves pediatric indication for Mycamine

Basilea awarded BARDA contract for novel antibiotic

Researchers at Novartis divulge novel androgen receptor antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...